<DOC>
	<DOC>NCT03056755</DOC>
	<brief_summary>Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrant</brief_summary>
	<brief_title>Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>patient is male or female 18 years or older Patient is identified PIK3CA mutant status Patient has confirmed HER2negative advanced breast cancer (aBC) Patient must be diagnosed with aBC with documented progression on or after CDK 4/6 treatment (adjuvant or metastatic setting) Patient has histological and/or cytological confirmed ER+ and/or PgR+ aBC Patient has either measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion must be present ECOG function of greater or equal to 2 Patient has adequate bone marrow function Patient has adequate liver and renal function patient has received prior treatment with any PI3K inhibitors patient with clinically manifest diabetes mellitus, or documented steroid induced diabetes mellitus Patient has a concurrent malignancy or malignancy within 3 years of study screening period, with the exception of adequately treated, basal or squamous cell carcinoma, nonmelanoma skin cancer or curatively resected cervical cancer Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapy History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis Bilateral diffuse lymphangitis carcinomatosis Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria: At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment Clinically stable CNS tumor at the time of screening untreated or without evidence of progressions for at least 4 weeks after treatment as determined by clinical examination and brain imaging (MRI or CT) during screening period and stable low dose of steroids for 2 weeks prior to initiating study treatment Patient with severe liver impairment (Child Pugh score B/C Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs Patient has documented pneumonitis which is active and requiring treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>CDK 4/6 inhibitor</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>letrozole</keyword>
	<keyword>HR+</keyword>
	<keyword>HER-negative</keyword>
	<keyword>post menopausal</keyword>
</DOC>